About TFF Pharmaceuticals
TFF Pharmaceuticals is a company based in Austin (United States) founded in 2018. TFF Pharmaceuticals has raised $22.17 million across 5 funding rounds from investors including HHS, NIAID and Liquid Venture Partners. The company has 15 employees. TFF Pharmaceuticals offers products and services including Biopharmaceutical Drugs. TFF Pharmaceuticals operates in a competitive market with competitors including MediciNova, Theravance Biopharma, Elastrin, Chance Pharmaceuticals and ReAlta Life Sciences, among others.
- Headquarter Austin, United States
- Employees 15
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website tffpharma.com
- Legal Name Tff Pharmaceuticals, Inc.
- Annual Revenue$733.87 K (USD)48as on Dec 31, 2023
- Net Profit-$21.24 M (USD)33as on Dec 31, 2023
- EBITDA-$21.89 M (USD)31as on Dec 31, 2023
- Total Equity Funding$22.17M (USD)
in 5 rounds
- Latest Funding Round$864.95K (USD), Grant
Jul 2023
- InvestorsHHS
& 2 more
- Employee Count15
Products & Services of TFF Pharmaceuticals
TFF Pharmaceuticals offers a comprehensive portfolio of products and services, including Biopharmaceutical Drugs.
Focuses on clinical stage pharmaceutical innovations for research purposes
Funding Insights of TFF Pharmaceuticals
TFF Pharmaceuticals has successfully raised a total of $22.17M across 5 strategic funding rounds. The most recent funding activity was a Grant round of $864.95 thousand completed in July 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $22.17M
- Total Rounds 5
- Last Round Grant — $864,948
- First Round $14M
(Apr 2018)
- Investors Count 3
All 5 funding rounds of TFF Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2023 | $864,948 | Grant | – | – | |
| Jun 2023 | $2.97M | Grant | – | – | |
| Aug 2020 | $25.9M | Post-IPO | – | – | – |
| May 2019 | $8.17M | Series A | – | – | – |
| Apr 2018 | $14M | Series A | – | Liquid Venture Partners | – |
3 investors in total: 3 institutional.
Investors in TFF Pharmaceuticals
TFF Pharmaceuticals has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include HHS, NIAID and Liquid Venture Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - | |
- | – | niaid.nih.gov | - | |
Liquid Venture Partners is engaged in assisting young companies with transformative technologies to go public through Nasdaq IPOs. | – | liquidventure.com | Ketchum, United States |
Investor details for TFF Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of TFF Pharmaceuticals
22 people are tracked at TFF Pharmaceuticals (9 in leadership, 12 in board & advisors, 1 in team); the tracked headcount is 15.
| Name | Role | Group |
|---|---|---|
Harlan Weisman | CEO | Leadership |
G.J. Davenport | VP of Government & Strategic Initiatives | Leadership |
Kirk Coleman | CFO | Leadership |
Zamaneh Mikhak | Chief Medical Officer | Leadership |
Chris Cano | COO & VP of Business Development | Leadership |
John J. Koleng | VP of Product Development & Manufacturing | Leadership |
John Koleng Ph.d., R.ph. | Vice President, Product Development And Manufacturing | Leadership |
Donald E. Owens III | Director Of Product Development | Leadership |
Dale J. Christensen | VP of Preclinical Research & Early Development | Leadership |
Ted M. Ross | Scientific Advisor | Board & advisors |
David Denning | Scientific Advisor | Board & advisors |
Aaron Fletcher | Chairman | Board & advisors |
Mike Saag | Scientific Advisor | Board & advisors |
Robert O. Williams III | Technology Inventor & Special Advisor | Board & advisors |
Anthony Hickey | Senior Research & Development Advisor & Chairman of the Scientific Advisory Board | Board & advisors |
Jay Peters | Scientific Advisor | Board & advisors |
Drew Weissman | Scientific Advisor | Board & advisors |
David N. Cornfield | Scientific Advisor | Board & advisors |
Brandi Roberts | Director | Board & advisors |
Robert S. Mills | Director | Board & advisors |
2 more people are available in the full profile.
Complete people profiles for TFF Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of TFF Pharmaceuticals
4 dated milestones of TFF Pharmaceuticals across 5 years, from founding to its latest funding, stage changes and deals.
- Founded TFF Pharmaceuticals is founded.
- Funding First funding round of $14.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Grant, of $865K.
Competitors of TFF Pharmaceuticals
TFF Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as MediciNova, Theravance Biopharma, Elastrin, Chance Pharmaceuticals and ReAlta Life Sciences, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| medicinova.com | 2000 | San Diego, United States | $83.94M | 13 | Small-molecule therapeutics are developed for asthma, COPD, and neurologic diseases. | |
| theravance.com | 2001 | Francisco, United States | – | 99 | Therapeutics for inflammatory and immunological diseases are developed. | |
| elastrin.com | 2017 | Simpsonville, United States | $17.25M | – | Developer of therapeutic targets related to arterial and lung diseases | |
| chancepharmaceuticals.com | 2015 | Hangzhou, China | $31.03M | – | Inhalation therapies for pulmonology disorders are developed. | |
| realtalifesciences.com | 2018 | Norfolk, United States | $81.5M | 19 | Therapeutic drugs for acute inflammatory and rare diseases are developed. | |
| topigen.com | 2000 | Montreal, Canada | $50.09M | – | Respiratory disorder treatments are developed by this clinical-stage biopharmaceutical firm. | |
| elevationpharma.com | 2007 | San Diego, United States | $77M | – | Developer of aerosol drug products for COPD patients | |
| axikin.com | 2008 | San Diego, United States | $12.5M | 2 | US-based, clinical-stage biopharma developing chemokine receptor targeting small molecules for respiratory, inflammatory and autoimmune diseases | |
| o11-biomedical.com | 2024 | Aachen, Germany | – | – | Therapeutics for respiratory diseases, including hypercapnia treatments, are developed. |
Detailed competitors of TFF Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of TFF Pharmaceuticals
The website of TFF Pharmaceuticals (tffpharma.com) receives about 1.5K visits a month.
- Monthly visits1.5K
▼ 30.5% vs previous month
Latest news on Tff Pharmaceuticals
Complete news archive for TFF Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to TFF Pharmaceuticals
10 companies that operate in the same segment as TFF Pharmaceuticals (Pulmonology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Portable oxygen concentrators are supplied for respiratory therapy needs. | 2001 | Goleta, California, United States | USD 51.65 M | USD 348.67 M | 766 | |
Cancer detection diagnostics assays are developed and offered. | 2005 | Boulder, Colorado, United States | USD 200.16 M | USD 88.5 M | 273 | |
Therapeutic devices for nasal breathing improvement are developed. | 2011 | Sunnyvale, California, United States | USD 176.4 M | – | 66 | |
Non-invasive breath-based diagnostics for cancer and infectious diseases are developed. | 2004 | Cambridge, Cambridgeshire, United Kingdom | USD 166.55 M | – | 202 | |
Protein biologics are developed for treating rare diseases. | 2005 | San Diego, California, United States | USD 171.52 M | USD 190 K | 59 | |
Therapeutics for rare respiratory diseases are developed by Savara Pharma. | 2008 | Austin, Texas, United States | USD 67.82 M | – | 59 | |
Developer of smart devices for treating pulmonary diseases | 1998 | Redwood City, California, United States | USD 280.91 M | USD 90.5 M | 291 | |
A norovirus vaccine is developed for infection prevention. | 2021 | Boston, Massachusetts, United States | USD 135 M | – | 14 | |
Oral small molecule drugs for chronic diseases are developed. | 2017 | San Francisco, California, United States | USD 233 M | – | 163 | |
Precision medicines for lung-related diseases are developed. | 2015 | Menlo Park, California, United States | USD 371 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about TFF Pharmaceuticals
TFF Pharmaceuticals was founded in 2018.
TFF Pharmaceuticals is headquartered in Austin, United States. It is registered at Austin, Texas, United States.
Harlan Weisman is the current CEO of TFF Pharmaceuticals.
TFF Pharmaceuticals is a funded company, having raised a total of $22.17M across 5 funding rounds to date. The company's 1st funding round was a Series A of $14M, raised on Apr 2018.
TFF Pharmaceuticals has 15 employees.
Annual revenue of TFF Pharmaceuticals is $733.87K as on Dec 31, 2023.
TFF Pharmaceuticals was founded in 2018 in Austin, United States, focusing on the pharmaceutical sector. Proprietary thin-film freezing technology is employed to produce dry powder inhalers for respiratory drugs. This approach is applied to small molecules, biologics, and combination therapies targeting chronic respiratory conditions. Operations center on advancing inhalation delivery systems for improved drug administration.
TFF Pharmaceuticals's top competitors include Theravance Biopharma, MediciNova and ReAlta Life Sciences.
TFF Pharmaceuticals offers Biopharmaceutical Drugs.
TFF Pharmaceuticals has 3 investors. Key investors include HHS, NIAID, and Liquid Venture Partners.
TFF Pharmaceuticals operates through Tff Pharmaceuticals, Inc..